Concepedia

Publication | Closed Access

Efficacy and Safety of Transdermal Oxybutynin in Patients With Urge and Mixed Urinary Incontinence

DOI

209

Citations

39

References

2002

Year

Roger R. Dmochowski, G. Willy Davila, Norman R. Zinner, Marc Gittelman, Daniel R. Saltzstein, Sydney Lyttle, Steven W. Sanders
The Journal of Urology

Abstract

Doses of 2.6 and 3.9 mg. oxybutynin TDS daily improve overactive bladder symptoms and quality of life, and are well tolerated. Transdermal oxybutynin is an innovative new treatment for overactive bladder.

References

YearCitations

Page 1